Mulder H, Steenbergen J, Haanen C
Br J Haematol. 1977 Mar;35(3):419-27. doi: 10.1111/j.1365-2141.1977.tb00602.x.
Nineteen patients with primary myelofibrosis and myeloid metaplasia (MMM), who fulfilled well-defined criteria, underwent elective splenectomy as soon as the diagnosis was confirmed. Nine patients developed postoperative complications such as intra-abdominal bleeding (three), rupture of the inferior vena cava (one), ascites (two), Australia antigen-positive hepatitis (three), mesenteric artery thrombosis (one) and pneumonia (one). One patient died within a month of the operation due to secondary intra-abdominal infection. The mean age of the patients at splenectomy was 56 years and the mean duration of their disease 2.4 years. The median actuarial survival after operation was 51 months. Although the series of patients is small, it seems that splenectomy did not have an adverse effect on life expectancy. The haematological status and the quality of life improved after splenectomy in 17 of 19 patients. The results warrant a further trial with elective splenectomy in an early stage of MMM.
19例符合明确标准的原发性骨髓纤维化伴髓外化生(MMM)患者,一旦确诊便接受了择期脾切除术。9例患者出现了术后并发症,如腹腔内出血(3例)、下腔静脉破裂(1例)、腹水(2例)、澳大利亚抗原阳性肝炎(3例)、肠系膜动脉血栓形成(1例)和肺炎(1例)。1例患者在术后1个月内死于继发性腹腔内感染。接受脾切除术患者的平均年龄为56岁,疾病平均病程为2.4年。术后的中位精算生存期为51个月。尽管患者系列数量较少,但脾切除术似乎对预期寿命没有不利影响。19例患者中有17例在脾切除术后血液学状况和生活质量得到改善。这些结果值得在MMM早期对择期脾切除术进行进一步试验。